Toys remain steadfast on holiday shopping lists, poll finds
NEW YORK Toys continue to dominate wish lists this holiday season, according to a new poll by Harris Interactive.
Of 3,084 U.S. adults surveyed online between Oct. 11 and 18, 53% of respondents said that they plan to purchase toys as gifts this year. What’s more, nearly 3-out-of-4 consumers in a household with children (73%) said they will purchase toys as gifts this year.
Topping the toys list this year includes books (43%), video games (32%) and board games (32%). Top gift picks also include:
Arts and crafts (29%);
Building blocks and bricks (22%);
Sports equipment (21%);
Handheld electronic games (20%); and
Game consoles (13%).
But while it seems many Americans will buy toys this holiday season, toy manufacturers should expect similar sales as last year — 54% of Americans in 2009 said they planned to purchase toys as gifts. In terms of where these toy dollars will be spent, more than half of toy purchasers mostly will be shopping for toys at large discount stores (54%), while one-quarter (23%) mostly will shop online for toys this year. One-in-10 (11%) mostly will shop at a national toy retail chain store, while 5% will shop at a local, privately owned specialty toy store.
Subs keeps up with urban trend
NEW YORK — A new urban fashion accessory has hit the market.
Hatch Ventures recently introduced Subs, designed for consumers who wear baggy pants well below the waistline. Like traditional suspenders, Subs are designed to keep pants from falling down by cinching around the waist and are worn underneath a shirt. The wearer can control how long they want their pants to "sag," and prevent pants from falling any lower.
Subs carry a suggested retail price of $34.95 and currently are available on Hatch Ventures’ website, HatchVentures.com.
Amgen’s Xgeva receives FDA approval
SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for preventing skeletal injuries in patients whose cancer has spread to the bone.
The FDA announced Friday the approval of Thousand Oaks, Calif.-based biotech company Amgen’s Xgeva (denosumab) for bone metastases.
The drug is a monoclonal antibody that targets RANKL, a protein involved in the destruction of bones in patients with cancer. Other treatments for similar conditions include Novartis’ drugs Zometa (zoledronic acid) and Aredia (pamidronate disodium).
“Bone metastases represent a major cause of pain and suffering in patients with cancer and can affect a patient’s quality of life,” FDA Office of Oncology Drug Products director Richard Pazdur said. “Xgeva has a different mechanism of action than currently approved drugs aimed at reducing bone complications from cancer.”